For those who prefer verbal presentations, here is some of the text, and a link to the complete article. Please note that the CURRENT STANDARD OF CARE for head and neck cancer is the more aggressive treatment regimen. Therefore, this is what most patients must endure -- and this is the one for which Brilacidin-OM is so important.

Quote:

---

Trial Results—Clear Efficacy Signal in the More Aggressive Chemotherapy Regimen

Brilacidin-OM was more effective in decreasing the incidence of SOM in Head and Neck Cancer (HNC) patients receiving the more aggressive chemotherapy regimen — cisplatin administered in a higher concentration (80-100 mg/m2), every 21 days — as compared to lower concentrations of cisplatin (30-40 mg/m2) administered weekly.

For the modified Intent-to-Treat (mITT) population, Brilacidin-OM in the aggressive chemotherapy regimen reduced the relative incidence of SOM by 65.0% ([incidence control - incidence active] / incidence control) where the group incidence rates were Brilacidin: 25.0%; placebo: 71.4% (p=0.048). For the Per Protocol (PP) population, Brilacidin-OM in the aggressive chemotherapy regimen similarly reduced the relative incidence of SOM by 80.3% (Brilacidin: 14.3%; placebo: 72.7%) (p=0.025). The q3wk dosing regimen aligns with current standard-of-care for cisplatin chemotherapy. Brilacidin-OM also delayed the onset of SOM and reduced the duration of SOM. Treatments appeared well-tolerated with good safety.

---

http://www.ipharminc.com/new-blog/2018/9/24/b...l-om-drugs